Phibro Animal Health Corporation (NASDAQ:PAHC) Given Average Rating of “Hold” by Brokerages

Phibro Animal Health Corporation (NASDAQ:PAHC) has been given a consensus rating of “Hold” by the five brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $42.50.

Several analysts recently issued reports on the company. Citigroup reduced their price target on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a research note on Thursday, May 14th. Wall Street Zen downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Weiss Ratings downgraded shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, June 15th. Finally, Zacks Research downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 21st.

Phibro Animal Health Stock Up 1.5%

PAHC stock opened at $31.83 on Friday. The business has a 50 day moving average price of $39.23 and a two-hundred day moving average price of $44.13. Phibro Animal Health has a twelve month low of $24.58 and a twelve month high of $60.08. The company has a market cap of $1.29 billion, a price-to-earnings ratio of 13.66, a P/E/G ratio of 0.47 and a beta of 0.46. The company has a quick ratio of 1.26, a current ratio of 3.17 and a debt-to-equity ratio of 1.97.

Phibro Animal Health (NASDAQ:PAHC) last issued its earnings results on Wednesday, May 6th. The company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.72 by $0.04. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.The company had revenue of $383.54 million during the quarter, compared to the consensus estimate of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. Analysts anticipate that Phibro Animal Health will post 3.08 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, June 24th. Stockholders of record on Wednesday, June 3rd were given a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.5%. The ex-dividend date was Wednesday, June 3rd. Phibro Animal Health’s dividend payout ratio is presently 20.60%.

Insider Buying and Selling at Phibro Animal Health

In related news, CEO Jack Bendheim sold 4,528 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $48.49, for a total transaction of $219,562.72. Following the completion of the sale, the chief executive officer directly owned 56,152 shares in the company, valued at $2,722,810.48. This represents a 7.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 46,768 shares of company stock worth $2,560,222. Corporate insiders own 50.13% of the company’s stock.

Hedge Funds Weigh In On Phibro Animal Health

Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Phibro Animal Health by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 1,539,593 shares of the company’s stock valued at $57,519,000 after purchasing an additional 13,884 shares during the last quarter. State Street Corp raised its position in Phibro Animal Health by 5.4% in the fourth quarter. State Street Corp now owns 942,279 shares of the company’s stock valued at $35,204,000 after purchasing an additional 48,243 shares during the last quarter. Millennium Management LLC raised its stake in shares of Phibro Animal Health by 4,227.1% during the fourth quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock valued at $23,959,000 after acquiring an additional 626,492 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Phibro Animal Health by 5.8% during the first quarter. Renaissance Technologies LLC now owns 576,735 shares of the company’s stock valued at $31,899,000 after acquiring an additional 31,435 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Phibro Animal Health by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 569,111 shares of the company’s stock valued at $21,265,000 after acquiring an additional 21,951 shares during the last quarter. 99.34% of the stock is currently owned by institutional investors.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.